- Cambrex will partner with Lilly Catalyze360-ExploR&D to provide clinical development capabilities for Lilly’s biotech collaborators.
- Services will be primarily hosted at Cambrex’s Longmont, Colorado, facility, specialising in early-stage small molecule development.
Cambrex, a global CDMO, announced its partnership with Lilly Catalyze360-ExploR&D, the innovation arm of Eli Lilly and Company, to provide development services for Lilly’s biotech collaborators. The collaboration will accelerate early-stage drug development through Cambrex’s expertise in drug substance, drug product, and analytical services.
Primarily based at Cambrex’s Longmont, Colorado, facility, the agreement encompasses process development, manufacturing, and cGMP testing. Additional support will be drawn from Cambrex’s global network as required.
“Through this alliance, we aim to expedite product development for biotech collaborators,” said Brandon Fincher, President of Early Stage Development & Testing at Cambrex.
Lilly Catalyze360 supports emerging medicines through innovation pillars, including ExploR&D, which integrates enterprise knowledge and advanced R&D capabilities. This agreement reflects a strategic effort to propel biotech innovations toward clinical success.